Searchable abstracts of presentations at key conferences in endocrinology

ea0049ep239 | Bone & Osteoporosis | ECE2017

Endocrine disorders in treatment-naïve male patients with HIV infection

Kalogeris Nikolaos , Nezi Markella , Chini Maria , Lioni Athina , Sakka Vissaria , Mangafas Nikolaos , Kaoustou Styliani , Lazanas Marios , Vryonidou Andromachi

Objective: To investigate endocrine disorders concerning bone metabolism, thyroid and gonadal axis in treatment–naïve HIV-infected male patients.Subjects and methods: We studied 70 male, treatment-naïve patients (stage A=60, stage B=10) from the Infectious Diseases Unit of our Hospital. Anthropometric indices were measured and BMI was calculated for each participant. Blood samples were obtained after an overnight fasting for the evaluation...

ea0063p664 | Interdisciplinary Endocrinology 1 | ECE2019

Differential regulation of 5β-reductase (AKR1D1) expression and activity by glucocorticoids in human and rodent liver

Nikolaou Nikolaos , Morgan Stuart , Larner Dean , Sharp Anna , Raouf Zachariah , Hughes Beverly , Digweed Dena , Whitaker Martin , Ross Richard , Lavery Gareth , Arlt Wiebke , Gathercole Laura , Tomlinson Jeremy

The prevalence of metabolic syndrome and its hepatic manifestation, non-alcoholic fatty liver disease (NAFLD), continues to escalate. Glucocorticoids (GCs) and bile acids (BAs) are established regulators of metabolic phenotype. 5β-reductase (AKR1D1) is highly expressed in human and rodent liver, where it inactivates steroid hormones and catalyses a fundamental step in BA synthesis. We have previously demonstrated that AKR1D1 modulates hepatic GC availability and GC recept...

ea0059oc3.6 | Obesity & diabetes | SFEBES2018

5β-reductase (AKR1D1) is a potent regulator of hepatic insulin sensitivity, carbohydrate and lipid metabolism in vitro and in vivo

Nikolaou Nikolaos , Gathercole Laura , Marchand Lea , Althari Sara , Green Charlotte , McNeil Catriona , Harris Shelley , van de Bunt Martijn , Arlt Wiebke , Hodson Leanne , Tomlinson Jeremy

Steroid hormones and BAs are established regulators of metabolic phenotype. 5β-reductase (AKR1D1) is highly expressed in the liver where it inactivates steroid hormones and catalyses a fundamental step in bile acid (BA) synthesis. We have hypothesised that AKR1D1 plays a crucial regulatory role in hepatic metabolic homeostasis. Genetic manipulation of AKR1D1 was performed in human liver HepG2 and Huh7 cells. Expression changes were confirmed by qPCR and western blotting, ...

ea0037gp.04.01 | Steroids | ECE2015

Dual 5α-reductase inhibition causes hepatic lipid accumulation in man

Hazlehurst Jonathan , Oprescu Andrei , Nikolaou Nikolaos , Grinbergs Annabel , Davies Nigel , Flintham Robert , Hughes Beverley , Taylor Angela , Yu Jinglei , Wagenmakers Anton , Tomlinson Jeremy

5α reductases 1 and 2 (SRD5A1 and SRD5A2) metabolise cortisol into inactive 5α-dihydrocortisol contributing to the regulation of cortisol availability in addition to their established role in the generation of dihydrotestosterone from testosterone. Dutasteride and finasteride are commonly prescribed to patients with benign prostatic hyperplasia but their potential metabolic effects have only recently been identified. Dutasteride inhibits both SRD5A1and SRD5A2 whilst ...

ea0037gp.04.04 | Steroids | ECE2015

Regulation of lipogenesis in human hepatocytes by androgens, glucocorticoids, and 5α-reductase

Nikolaou Nikolaos , Nasiri Maryam , Parajes Sylvia , Krone Nils , Mastorakos George , Valsamakis George , Hughes Beverly , Taylor Angela , Bujalska Iwona , Gathercole Laura , Tomlinson Jeremy

Non-alcoholic fatty liver disease (NAFLD) is rapidly becoming the commonest cause of liver cirrhosis and leading indication for liver transplant worldwide. It is tightly associated with obesity and type 2 diabetes, yet the precise mechanisms that drive its aetiology are not fully defined. Dysregulation of both glucocorticoid and androgen metabolism has been implicated in its pathogenesis. The availability of these hormones to bind and activate their receptors is mainly regulat...

ea0056oc6.1 | Genetic and environmental determinants of obesity and insulin resistance | ECE2018

5β-reductase (AKR1D1) is a potent regulator of hepatic insulin sensitivity, carbohydrate and lipid metabolism in vitro and in vivo

Nikolaou Nikolaos , Gathercole Laura , Marchand Lea , Althari Sara , Green Charlotte , McNeil Catriona , Harris Shelley , van de Bunt Martijn , Arlt Wiebke , Hodson Leanne , Tomlinson Jeremy

Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic disease. 5β-reductase (AKR1D1) is highly expressed in human liver where it inactivates steroid hormones and, in parallel, catalyzes a fundamental step in bile acid synthesis. Steroid hormones, including glucocorticoids, as well as bile acids (BAs) are established regulators of metabolic phenotype. We have hypothesized that AKR1D1 plays a crucial regulatory role in hepatic metabolic homeost...

ea0092op-11-03 | Oral Session 11: Autoimmunity / Hyperthyroidism | ETA2023

Effects of acute triiodothyronine treatment in patients with anterior myocardial infarction undergoing primary angioplasty: does infarct size matter?

Pantos Constantinos , Grigoriou Konstantinos , Trikas Athanasios , Pissimisis Evangelos , Stougiannos Pavlos , Dimopoulos Antonios , Linardakis Sarantos , Alexopoulos Nikolaos , Evdoridis Costas , Gavrielatos Gerasimos , Patsourakos Nikolaos , Papakonstantinou Nikolaos , Theodosis-Georgilas Anastasios , Mourouzis Iordanis

Objectives: Triiodothyronine (LT3) administration for 48hours in patients undergone primary angioplasty showed favourable effects on cardiac function and remodelling early after myocardial infarction (Thy-Repair, EudraCT 2016-000631-40, Thyroid 2022 Jun;32(6):714-724). The present study investigated whether this beneficial effect was dependent on the severity of infarct size. The extent of infarct size is one of the main determinants of morbidity and mortality after myocardial...

ea0077p239 | Reproductive Endocrinology | SFEBES2021

The rate of progression of atherosclerosis in menopause is associated with levels of circulating amyloid beta 1-40

Armeni Eleni , Delialis Dimitrios , Georgiopoulos Georgios , Tual-Chalot Simon , Vlachogiannis Nikolaos , Patras Raphael , Aivalioti Evmorfia , Augoulea Areti , Tsoltos Nikolaos , Soureti Anastasia , Stellos Konstantinos , Stamatelopoulos Kimon , Lambrinoudaki Irene

Background: Cardiovascular disease remains the leading cause of death worldwide, affecting both sexes. Awareness and prevention practices aiming to control cardiovascular risk in women remain inadequate. On the other hand, circulating amyloid β 1-40 (Aβ1-40) is a proatherogenic peptide, closely linked with the process of aging. We aimed to evaluate the possible association between the progression of atherosclerosis in postmenopausal women and the role of Aβ1-40 ...

ea0081p274 | Adrenal and Cardiovascular Endocrinology | ECE2022

Progression of atherosclerosis after the menopause and the role of circulating Amyloid Beta 1-40

Lambrinoudaki Irene , Armeni Elena , Delialis Dimitrios , Georgiopoulos Georgios , Tual-Chalot Simon , Vlachogiannis Nikolaos , Patras Raphael , Aivalioti Evmorfia , Augoulea Areti , Tsoltos Nikolaos , Soureti Anastasia , Stellos Konstantinos , Stamatelopoulos Kimon

Background: A large body of evidence is supporting that the incidence of adverse cardiovascular events is increasing signfiicantly after the menopausal transition. Primary prevention practices continue to propose evolving algorithms, in an attempt to accurately estimate the actual female cardiovascular risk at midlife. Irrespectively of these attempts, considerable unrecognized cardiovascular disease (CVD) risk remains unexplained, beyond traditional risk factors (TRFs). On th...

ea0067o56 | Oral Presentations | EYES2019

Effects of novel antidiabetic agents on the arterial wall elastic properties as a marker of vascular function in patients with type 2 diabetes mellitus

Stampouloglou Panagiota , Siasos Gerasimos , Bletsa Evanthia , Batzias Konstantinos , Paschou Stavroula A , Antonopoulos Alexis , Tsigkou Vasiliki , Oikonomou Evangelos , Gouliopoulos Nikolaos , Thanopoulou Anastasia , Noutsou Marina , Vryonidou Andromahi , Tentolouris Nikolaos , Tousoulis Dimitris

Background: Arterial stiffness is a well-established surrogate marker of vascular properties and arterial dysfunction in patients with type 2 diabetes mellitus (DM2). We aimed to investigate whether optimization of DM2 therapy with, additional to metformin, novel antiglycemic agents may improve arterial wall properties and achieve better glycemic control.Methods: We enrolled 99 consecutive patients (male gender=63.3%) receiving metformin for DM2 who did ...